Zobrazeno 1 - 2
of 2
pro vyhledávání: '"Dawson, Sarah"'
Autor:
Coles, Alasdair, Azzopardi, Laura, Kousin-Ezewu, Onajite, Mullay, Harpreet, Thompson, Sara, Jarvis, Lorna, Davies, Jessica, Howlett, Sarah, Rainbow, Daniel, Babar, Judith, Sadler, Timothy, Brown, William, Needham, Edward, May, Karen, Georgieva, Zoya, Handel, Adam, Maio, Stefano, Deadman, Mary, Rota, Ioanna, Hollander, Georg, Dawson, Sarah, Jayne, David, Seggewiss-Berhardt, Ruth, Douek, Daniel, Isaacs, John, Jones, Joanne
Background: The lymphocyte-depleting antibody alemtuzumab is a highly effective treatment of relapsing-remitting multiple sclerosis (RRMS); however 50% of patients develop novel autoimmunity post-treatment. Most at risk are individuals who reconstitu
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::522f0d03529120d4d4d5f9794e364e54
Autor:
Laura Azzopardi, T J Sadler, Joanne L. Jones, Stefano Maio, Sara A. J. Thompson, Ioanna A. Rota, Daniel B. Rainbow, Georg A. Holländer, Jessica L. Davies, J Babar, Edward Needham, Harpreet Kaur Mullay, S Dawson, R Seggewiss-Bernhardt, Brown Jwl., Onajite Kousin-Ezewu, Sarah Howlett, John D. Isaacs, D C Douek, Mary E. Deadman, David Jayne, Zoya Georgieva, K. May, Adam E. Handel, Lorna B. Jarvis, Alasdair Coles
Publikováno v:
JCI Insight
BACKGROUND The lymphocyte-depleting antibody alemtuzumab is a highly effective treatment for relapsing-remitting multiple sclerosis (RRMS); however, 50% of patients develop novel autoimmunity after treatment. Most at risk are individuals who reconsti
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6162262bf66c0e2304991787786a1d80
https://ora.ox.ac.uk/objects/uuid:5fe18699-f27b-47a1-91be-f24f76f1eccd
https://ora.ox.ac.uk/objects/uuid:5fe18699-f27b-47a1-91be-f24f76f1eccd